Jake Van Naarden

Jake Van Naarden

Executive Vice President and President, Lilly Oncology and Head of Corporate Business DevelopmentatEli Lilly & Co· In proxies 2021–2025

Pay in FY2025+31% from the year before

Jake Van Naarden was paid $7.6M in FY2025 (Dec), up 31%.

PayNo stock prices for these years
Pay is from the Summary Compensation Table of each Eli Lilly & Co proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Eli Lilly & CoPublic company · 5 yr
    • Executive Vice President and President, Lilly Oncology and Head of Corporate Business Development2021 – Present · 5 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?